Pemetrexed and Pembrolizumab for the Treatment of Recurrent and/or Metastatic Salivary Gland Cancer
Status:
Recruiting
Trial end date:
2026-06-03
Target enrollment:
Participant gender:
Summary
This phase II trial studies the effect of pemetrexed and pembrolizumab in treating patients
with salivary gland cancer that has come back (recurrent) and/or has spread to other places
in the body (metastatic). Chemotherapy drugs, such as pemetrexed, work in different ways to
stop the growth of tumor cells, either by killing the cells, by stopping them from dividing,
or by stopping them from spreading. Immunotherapy with monoclonal antibodies, such as
pembrolizumab, may help the body's immune system attack the cancer, and may interfere with
the ability of tumor cells to grow and spread. The purpose of this study is to evaluate
whether pembrolizumab, an immunotherapy drug, in combination with the chemotherapy drug,
pemetrexed, has an effect on advanced salivary gland cancer.